The global vaccines market was valued at USD 90.28 billion in 2023 and is expected to grow from USD 87.57 billion in 2024 to USD 159.28 billion by 2032, reflecting a CAGR of 7.8% during the forecast period. In North America, the vaccines market is projected to expand from USD 37.57 billion in 2023 to USD 38.75 billion in 2024.
The vaccines market is witnessing significant growth driven by increasing awareness of immunization, rising prevalence of infectious diseases, and continuous advancements in biotechnology. The global vaccines market encompasses a wide range of products including prophylactic and therapeutic vaccines aimed at preventing diseases such as influenza, hepatitis, HPV, and COVID-19, among others. Government initiatives, public health campaigns, and collaborations between pharmaceutical companies and global health organizations are further fueling market expansion. In addition, the vaccines market is benefiting from innovations in mRNA technology, recombinant vaccines, and novel delivery systems. As healthcare infrastructure improves across emerging economies, the vaccines market is expected to see enhanced accessibility and coverage, contributing to sustained growth.
Continue reading for more details:
https://www.fortunebusinessinsights.com/industry-reports/vaccines-market-101769
Market Segmentation
By type, the vaccines market includes live attenuated, inactivated, toxoid, subunit, conjugate, mRNA, and vector-based vaccines.
By indication, it covers pediatric vaccines, influenza, hepatitis, HPV, COVID-19, meningococcal, pneumococcal, and travel-related vaccines.
By age group, the vaccines market is segmented into pediatric, adolescent, adult, and geriatric populations.
By end-user, it includes hospitals, clinics, government programs, NGOs, and mobile immunization centers.
By distribution channel, the vaccines market operates through public procurement agencies, private distributors, and international health organizations.
List Of Key Companies Profiled in Vaccines Market:
GlaxoSmithKline plc. (U.K.)
Sanofi (France)
Pfizer Inc. (U.S.)
Merck & Co., Inc. (U.S.)
Novartis AG (Switzerland)
Emergent BioSolutions, Inc. (U.S.)
CSL Limited (Australia)
Inovio Pharmaceuticals, Inc. (U.S.)
Bavarian Nordic (Denmark)
Mitsubishi Tanabe Pharma Corporation (Japan)
Market Growth
The vaccines market is expanding rapidly due to increasing global immunization campaigns and greater focus on infectious disease prevention.
Rising investments in R&D and advancements in biotechnology are major drivers of the vaccines market.
The development of next-generation platforms such as mRNA and viral vector vaccines has added significant momentum to the vaccines market.
Government initiatives, public-private partnerships, and global health organization efforts are boosting access and funding within the vaccines market.
Greater awareness of vaccine-preventable diseases and post-pandemic preparedness strategies continue to stimulate the vaccines market.
Market Restraining Factors
High development costs and stringent regulatory processes may delay product launches in the vaccines market.
Cold chain logistics and infrastructure gaps, especially in low- and middle-income countries, hinder smooth delivery in the vaccines market.
Vaccine hesitancy driven by misinformation, religious beliefs, or safety concerns continues to limit full adoption in the vaccines market.
Uneven access to vaccines and limited local manufacturing capabilities in some regions affect equity in the vaccines market.
Intellectual property barriers and supply chain disruptions also pose risks to long-term growth of the vaccines market.
Regional Analysis
North America leads the vaccines market due to strong R&D infrastructure, government support, and well-established immunization programs.
Europe holds a significant share in the vaccines market, supported by harmonized vaccination schedules and pharmaceutical innovation.
Asia-Pacific is witnessing the fastest growth in the vaccines market, driven by population growth, healthcare investments, and domestic vaccine production.
Latin America is emerging in the vaccines market through expanded immunization coverage and improved access to public health funding.
Middle East and Africa present untapped opportunities for the vaccines market, with support from global alliances and rising demand for local production.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free)
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com